Xeljanz Lawsuit Updates & News | June 2024

Editorial Team

ConsumerShield

Reviewed By Adam Ramirez, J.D.

Editor

Read in 2 mins

This year, attorneys are also addressing the Xeljanz-blood clot lawsuits for the victims. Due to this reason, victims still have a chance to have the rightful compensation through legal guidance and support. By far, there are no declared court settlements and hearings for the Xeljanz-blood clot lawsuit.

  1. In April, scientific findings supported this allegation which included the conference of the British Society for Rheumatology 2023. It established the link between Janus Kinase inhibitors present in Xeljanz that boost the chances of cancer development among the victims.

  2. This includes research in Annals regarding rheumatic diseases, which states that severe cardiovascular fluctuations take place among the victims who are exposed to tofacitinib as compared to tumor necrosis among these patients.

  3. The European Medicines Agency imposed constraints on the prolonged usage of Xlejanz so that people can be in minimal contact with this drug, which can cause cardiac problems and blood clot development among them as well.

More About Xeljanz Lawsuit

Stay up to date

Get updates on all of our legal news on lawsuits, research and legal updates.